Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial.

Amir RazaghizadJiayi NiPedro MarquesThomas A MavrakanasMichael A TsoukasElite PossikThao HuynhJodi D EdwardsPeter LiuWalter SwardfagerFrederic Baroz Joao Pedro Ferreira Abhinav Sharma

Published in: Diabetes, obesity & metabolism (2024)

We identified four clinically distinct T2D phenotypes with differential CV risks. Canagliflozin reduced the risk of CV events, irrespective of the phenotype, emphasizing its broad therapeutic acceptability.

Keyphrases

type diabetes
study protocol
quality improvement
phase iii
clinical trial
glycemic control
phase ii
cardiovascular disease
human health
insulin resistance
randomized controlled trial
climate change
skeletal muscle